Advancements and New Treatment Options: Optimizing Care for Patients with Graft-vs-Host Disease - Episode 5

First-Line Therapy for Chronic GvHD

,

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

EP. 1: Overview of Graft-vs-Host Disease (GvHD)
EP. 2: How Does GvHD Typically Present?
EP. 3: Role of Biomarkers in Graft-vs-Host Disease
EP. 4: Staging Practices for Chronic Graft-vs-Host Disease
Now Viewing
EP. 5: First-Line Therapy for Chronic GvHD
EP. 6: Treating Patients With Steroid-Refractory Chronic GvHD
EP. 7: Approved Therapies for Steroid-Refractory Chronic GvHD
EP. 8: Therapies in Development for Chronic GvHD
EP. 9: Supportive Care and Medication Access in GvHD

Related Content:

Advancements and New Treatment Options: Optimizing Care for Patients with Graft-vs-Host DiseaseTulane Cancer CenterDana-Farber Cancer InstituteHematologic OncologyInsights
DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)
Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL
FDA Modifies REMS for Autologous CAR T-Cell Therapies in Hematologic Malignancies